OK, but this (ZEL has a drug and a little capital) is nothing new. The fact is we had 2 registration-enabling trials and now we have 1 - that's a significant negative change, and we only know about it now because of an offhand comment at another company's AGM.

(for completeness, according to the latest MD&A the Newsoara funding obligations were extended to run until December 2023.)